Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis

Abstract

The aim of this study was to provide further insight into the effective contribution of classical soluble HLA-A, B and C class Ia (sHLA-I) and non-classical soluble HLA-G class Ib (sHLA-G) molecules in immune dysregulation occurring in multiple sclerosis (MS). We evaluated by enzyme-linked immunosorbent assay (ELISA) technique intrathecal synthesis and cerebrospinal fluid (CSF) and serum levels of sHLA-I and sHLA-G in 69 relapsing-remitting (RR), 21 secondary progressive (SP) and 13 primary progressive (PP) MS patients stratified according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also tested, as neurological controls, 91 patients with other inflammatory neurological disorders (OIND) and 92 with non-inflammatory neurological disorders (NIND). Eighty-two healthy volunteers served as further controls for sHLA-I and sHLA-G determinations. An intrathecal production of sHLA-I and sHLA-G detected by specific indexes was significantly more frequent in MS patients than in controls (p<0.01). An intrathecal synthesis of sHLA-I was prevalent in clinically (p<0.02) and MRI active (p<0.001) MS, whereas a CSF-restricted release of sHLA-G predominated in clinically (p<0.01) and MRI stable (p<0.001) MS. sHLA-I levels were low in the serum of clinically active (p<0.001) and high in the CSF of MRI active (p<0.01) MS. Conversely, sHLA-G concentrations were decreased in the serum of clinically stable MS (p<0.01) and increased in the CSF of MRI inactive MS (p<0.001). The trends towards a negative correlation observed between CSF and serum concentrations and intrathecal synthesis of sHLA-I and sHLA-G in patients without evidence of clinical and MRI activity confirmed that intrathecal production and fluctuations in CSF and serum concentrations of sHLA-I and sHLA-G were reciprocal in MS. Our results suggest that, in MS, a balance between classical sHLA-I and non-classical sHLA-G products modulating both MRI and clinical disease activity in opposite directions may exist.

Keywords

cerebrospinal fluid intrathecal synthesis multiple sclerosis sHLA-G sHLA-I

Get full access to this article

View all access options for this article.

References

Compston A , Coles A. Multiple sclerosis . Lancet 2002; 359: 1221-1231 .

Lassmann H , Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal . Trends Immunol 2004; 25: 132-137 .

Babbe H , Roers A , Waisman A , Lassmann H , Goebels N , Hohlfeld R et al. Clonal expansion of CD8- T cells dominate the cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction . J Exp Med 2000; 192: 393-404 .

Huseby ES , Liggitt D , Brabb T , Schnabel B , ö hle`nC , Governman J. A pathogenic role for myelin-specific CD8- T cells in model for multiple sclerosis . J Exp Med 2001; 194: 669-676 .

Medana I , Martinic MA , Wekerle H , Neumann H. Transection of major histocompatibility complex class I-induced neuritis by cytotoxic T lymphocytes . Am J Pathol 2001; 159: 809-815 .

Killestein J , Eikelenboom MJ , Izeboud T , Kalkers NF , Ade`r HJ , Barkhof F et al. Cytokine producing CD8 T cells are correlated to MRI features of tissue destruction in MS . J Neuroimmunol 2003; 142: 141-148 .

Medana I , Gallimore A , Oxenius A , Martinic MA , Wekerle H , Neumann H. MHC class I-restricted killing of neurons by virus-specific CD8 T lymphocytes is effected through the Fas/FasL, but not the perforin pathway . Eur J Immunol 2000; 30: 3623-3633 .

Madakamutil LT , Maricic I , Sercarz E , Kumar V. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes . J Immunol 2003; 170: 2985-2992 .

Najafian N , Chitnis T , Salama AD , Zhu B , Benou C , Yuan X et al. Regulatory functions of CD8 CD28 T cells in an autoimmune disease model . J Clin Invest 2003; 112: 1037-1048 .

10.

Karandikar NJ , Crawford MP , Yan X , Ratts RB , Brenchley JM , Ambrozak DR et al. Glatiramer acetate (Copaxone) therapy induces CD8 T cell responses in patients with multiple sclerosis . J Clin Invest 2002; 109: 641-649 .

11.

Skulina C , Schmidt S , Dornmair K , Babbe H , Roers A , Rajewsky K et al. Multiple sclerosis: brain-infiltrating CD8- T cells persist as clonal expansion in the cerebrospinal fluid and blood . Proc Natl Acad Sci USA 2004; 101: 2428-3243 .

12.

Jacobsen M , Cepok S , Quak E , Happel M , Gaber R , Ziegler A et al. Oligoclonal expansion of memory CD8- cells in cerebrospinal fluid from multiple sclerosis patients . Brain 2002; 125: 538-550 .

13.

Redwine JM , Buchmeier MJ , Evans CF. In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection . Am J Pathol 2001; 159: 1219-1224 .

14.

Hofteberger R , Aboul-Enein F , Brueck W , Lucchinetti C , Rodriguez M , Schmidbauer M et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions . Brain Pathol 2004; 14: 43-50 .

15.

Kastrukoff LF , Morgan NG , Zecchini D , White R , Petkau AJ , Satoh J et al. A role for natural killer cells in the immunopathogenesis of multiple sclerosis . J Neuroimmunol 1998; 86: 123-133 .

16.

Takahashi K , Aranami T , Endoh M , Miyake S , Yamamura T. The regulatory role of natural killer cells in multiple sclerosis . Brain 2004; 127: 1917-1927 .

17.

McDonald JC , Adamashvili E. Soluble HLA: a review of literature . Hum Immunol 1998; 59: 387-403 .

18.

Zavazava N , Kronke M. Soluble HLA class I antigens induce apoptosis in alloreactive cytotoxic T lymphocytes . Nat Med 1996; 2: 1005-1010 .

19.

Puppo F , Contini P , Ghio M , Brenci S , Scudelletti M , Filaci G et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8 (-) Fas (CD95) (-) T lymphocytes . Int Immunol 2000; 12: 195-203 .

20.

Spaggiari MG , Contini P , Dondero A , Carosio R , Puppo F , Indiveri F et al. Soluble HLA class I induces NK cell apoptosis upon engagement of killer-activating HLA class I receptors through FASL-Fas interaction . Blood 2002; 100: 4098-4107 .

21.

Carosella ED , Moreau P , Aractingi S , Rouas-Freiss N. HLA-G: a shield against inflammatory aggression . Trends Immunol 2001; 22: 553-555 .

22.

LeMaoult J , Le Discorde M , Rouas-Freiss N , Moreau P , Menier C , McCluskey J et al. Biology and functions of human leukocyte antigen-G in health and sickness . Tissue Antigens 2003; 62: 273-284 .

23.

Rouas-Freiss N , Marchal RE , Kirszenbaum M , Dausset J , Carosella ED. The a1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors ? Proc Natl Acad Sci USA 1997; 94: 5249-5254 .

24.

Fournel S , Aguerre-Gir M , Huc X , Lenfant F , Alam A , Toubert A et al. Cutting edge: soluble HLA-G1 triggers CD95/CD 95 ligand-mediated apoptosis in activated CD8 cells by interacting CD8 . J Immunol 2000; 164: 6100-6104 .

25.

Contini P , Ghio M , Poggi A , Filaci G , Indiveri F , Ferrone S et al. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8 cells and inhibit cytotoxic T cell activity through CD8 ligation . Eur J Immunol 2003; 33: 125-134 .

26.

Kanai T , Fujii T , Kozuma S , Yamashita T , Miki A , Kikuchi A et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture . Mol Hum Reprod 2001; 7: 195-200 .

27.

Fuzzi B , Rizzo R , Criscuoli L , Noci I , Melchiorri L , Scarselli B et al. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy . Eur J Immunol 2002; 32: 311-315 .

28.

Moreau P , Cabestre FA , Menier C , Gauiard U , Gourand L , Dausset J et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes . Int Immunol 1999; 5: 803-811 .

29.

Wiendl H , Mitsdoerffer M , Hofmeister V , Wischhusen J , Bornemann A , Meyermann R et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape . J Immunol 2002; 168: 4772-4780 .

30.

Wiendl H , Behrens L , Maier S , Johnson MA , Weiss EH , Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G . Ann Neurol 2000; 48: 679-684 .

31.

Alvarez-Cermeño JC , Villar LM , Nocito M , Bootello A , Gonzales-Porque P. Intrathecal synthesis of soluble HLA class I antigens in multiple sclerosis . J Neuroimmunol 1992; 36: 77-79 .

32.

Filaci G , Contini P , Bronci S , Gazzola P , Lanza L , Scudeletti M et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients . Hum Immunol 1997; 54: 54-62 .

33.

Ott M , Seidl C , Westhoff U , Stecker K , Seifred E , Fischer PA et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis . Tissue Antigens 1998; 51: 301-304 .

34.

Fainardi E , Granieri E , Tola MR , Melchiorri L , Vaghi L , Rizzo R et al. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA-class I molecules . J Neuroimmunol 2002; 133: 151-159 .

35.

Fainardi E , Rizzo R , Melchiorri L , Castellazzi M , Govoni V , Caniatti L et al. Beneficial effect of interferon-b 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy . J Neuroimmunol 2004; 148: 206-211 .

36.

Fainardi E , Rizzo R , Melchiorri L , Vaghi L , Castellazzi M , Marzola A et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings . J Neuroimmunol 2003; 142: 149-158 .

37.

Poser CM , Paty DW , Scheimberger L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for MS: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

38.

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis . Ann Neurol 2001; 50: 121-127 .

39.

Lublin DF , Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey . Neurology 1996; 46: 907-911 .

40.

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS) . Neurology 1983; 33: 1444-1452 .

41.

Salden HJM , Bas BM , Hermas JT , Janson PC. Analytical performance of the three commercially available nephelometers compared quantifying protein in serum and cerebrospinal fluid . Clin Chem 1988; 34: 1594-1596 .

42.

Tibbling G , Link H , Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference value . Scand J Clin Lab Invest 1977; 37: 385-390 .

43.

Inostroza J , Munoz P , Espinoza R , Millaqueo L , Diaz P , Leiva L et al. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tuberculosis . Hum Immunol 1994; 40: 179-184 .

44.

Mitsdoerffer M , Schreiner B , Kieseier B , Neuhaus O , Dichgans J , Hartung H-P et al. Monocyte-derived HLA-Gacts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-b in vitro and in vivo: rationale for the therapy of multiple sclerosis . J Neuroimmunol 2005; 159: 155-164 .

45.

Bielekova B , Martin R. Development of biomarkers in multiple sclerosis . Brain 2004; 127: 1463-1478 .

46.

Ober C , Aldrich C , Rosinsky B , Roberton A , Walker MA , Willadsen S et al. HLA-G1 protein expression is not essential for fetal survival . Placenta 1998; 19: 127-132 .

47.

Wiendl H , Mitsdoerffer M , Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells . Semin Cancer Biol 2003; 13: 343-351 .